News
Dr Wolf will continue to represent Conelis e.V. as a chair
Dr Wolf will continue to represent Conelis e.V. as the acting chair of the Executive Board.
[...]
ECTRIMS 2022 Amsterdam
Dr Wolf will attend the congress of the European Committee on Treatment and Research in Multiple Sclerosis from 26-28 October 2022 in Amsterdam in person.
[...]
How to use biosimilars and generic NBCDs as MS DMTs?
just published and co-authored by Dr Wolf:
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendation.
[...]
Phase II for a 2nd-generation DHDOH inhibitor
just published and co-authored by Dr Wolf:
A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.
[...]
A Continued Role for Glatiramer Acetate?
just published and co-authored by Dr Wolf:
Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
[...]
Dr Wolf re-elected chair of Conelis
Dr Wolf has been re-elected chair of the Executive Board of Conelis e.V. during the association's General Assembly on 30 October 2020.
[...]IMSCOGS 2019 Amsterdam
Dr Wolf attends the 2019 annual meeting of the International Multiple Sclerosis Cognition Society (IMSCOGS) in Amsterdam's Compagnietheater on 6 and 7 June.
[...]
2nd drug approved with Lycalis' support
Yesterday, the US FDA approved Novartis' drug Mayzent® (siponimod) for treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome (CIS), relapsing remitting disease, and active secondary progressive disease, in adults. Lycalis has accompanied the development of siponimod since 2009.
[...]
AAN 2019 Philadelphia
Dr Wolf will attend the Annual Meeting of the American Academy of Neurology from 4-10 May 2019 in Philadelphia.
[...]
Dr Wolf elected chair of Conelis
Dr Wolf has been elected chair of the Executive Board of Conelis e.V. during the association's General Assembly on 12 October 2018.
[...]Dr Wolf re-elected treasurer of Conelis e.V.
Dr Wolf has been re-elected treasurer and member of the Executive Board of Conelis e.V. during the association's General Assembly on 7 October 2016.
[...]
ECTRIMS 2016 London
Dr Wolf attends the congress of the European Committee on Treatment and Research in Multiple Sclerosis from 14-17 September 2016 at the Excel Convention Centre in London.
[...]
AAN 2016 Vancouver
Dr Wolf will attend the Annual Meeting of the American Academy of Neurology from 15-21 April 2016 in Vancouver.
[...]
Landmark clinical equivalence study in MS
just published and co-authored by Dr Wolf:
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. A Randomized Clinical Trial.
[...]
ECTRIMS 2015 Barcelona
Dr Wolf attends the Congress of the European Committee on Treatment and Research in Multiple Sclerosis from 6-10 October 2015 at the Centre de Convencions Internacional in Barcelona.
[...]
Win a Day with Experts!
Berlin, Bremen (Germany) | 12 May 2015
SACURA, Conelis and GCP-Services International started a campaign to support biotech companies on the International Day of Clinical Trials
[...]
AAN 2015 Washington
Dr Wolf's poster presentation at AAN:
Selmaj K, Barkhof F, Wolf C, Belova A, Oberyé JJL, van den Tweel ERW, Mulder R, Koper NP, Voortman G, Cohen JA. Similar Local Tolerability Profiles Following Double-Blind Treatment With Generic or Branded Glatiramer Acetate in Multiple Sclerosis (full text).
[...]
EMSP Briefing and Networking Event
On invitation of the Executive Committee of the advocacy organisation European Multiple Sclerosis Platform (EMSP), Dr Wolf attended a Briefing and Networking Event in downtown Brussels.
[...]
Joint ECTRIMS/ACTRIMS 2014 Boston
Dr Wolf attends the Joint Congress of the European and American Committee on Treatment and Research in Multiple Sclerosis from 10-13 October 2014 at the John B. Hynes Veterans Memorial Convention Center in Boston.
[...]
Joint Congress of European Neurology
Dr Wolf attended the Joint Congress of European Neurology from 31-May to 3-June-2014 in Istanbul.
[...]
Step Award
The STEP Award is a competition designed to recognize innovative growth companies in Germany, Austria and Switzerland.
[...]
Win a Day with Experts!
Berlin, Bremen (Germany) | 21 May 2014
The German organisations Sacura GmbH, Conelis e.V. and GCP-Services International Ltd. & Co. KG launched a campaign to support young, small biotech/biopharmaceutical companies engaged in the development of new medicinal products and therapies in human health care.
Bionnale 2014 Berlin
Dr Wolf attended the Bionnale 2014 on 13-May-2014 in Berlin and represented Conelis e.V. during the Contact Forum.
[...]
Dr Wolf re-elected treasurer of Conelis e.V.
Dr Wolf has been re-elected treasurer and member of the Executive Board of Conelis e.V. during the association's General Assembly on 18 October 2013.
[...]EMA Workshop Multiple Sclerosis Guideline
Dr Wolf will attend the European Medicines Agency's Workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis on 17 October 2013 in London.
[...]
Lecture on MS Drug Development (Düsseldorf)
Dr Christian Wolf was invited to lecture about MS drug development during the 15. Jahreskongress Klinische Pharmakologie on 10 October 2013 in Düsseldorf.
[...]
ECTRIMS 2013 Copenhagen
Dr Wolf will attend the Congress of the European Committee on Treatment and Research in Multiple Sclerosis from 1-5 October 2013 at the Bella Center in Copenhagen.
[...]
AAN 2013 San Diego
Dr Wolf will attend the Annual Meeting of the American Academy of Neurology from 16-23 March 2013 in San Diego.
[...]
Patient-volunteer studies in Multiple Sclerosis
just published and co-authored by Dr Wolf:
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study.
BAPU 2012 Antwerpen
Dr Wolf attended the conference "Early Clinical Drug Development towards 2020" held by the Belgian Association of Phase I Units in Antwerp's Astrid Hotel on 9 November 2012.
[...]
ECTRIMS 2012 Lyon
Dr Wolf will attend the Congress of the European Committee on Treatment and Research in Multiple Sclerosis from 10-13 October 2012 in Lyon.
[...]
Lycalis registered as an EU trademark
The name »Lycalis« has been approved as a Community trademark by the EU's Alicante-based »Office for Harmonization in the Internal Market« (OHIM) under the number 010711703.
[...]
House of Lords
On invitation of Richmond Pharmacology Ltd, Dr Wolf attended a reception of Lord McColl of Dulwich in the House of Lords (London) held on behalf of the Clinical Contract Research Association.
[...]
ENS 2012 Prague
Dr Wolf will attend the Annual Meeting of the European Neurological Society from 9-12 June 2012 in Prague.
[...]
AAN 2012 New Orleans
Dr Wolf will attend the Annual Meeting of the American Academy of Neurology from 21-28 April 2012 in New Orleans.
[...]
Long-Term Disability in Multiple Sclerosis
just published and co-authored by Dr Wolf:
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
Patient-volunteer studies in Multiple Sclerosis
just published and co-authored by Dr Wolf:
Benefits of a Single Versus Multicenter Approach in Early-Phase Patient Studies. A Case Study of Multiple Sclerosis Patients.
[...]Dr Wolf elected treasurer of Conelis e.V.
Dr Wolf has been elected treasurer and member of the Executive Board of Conelis e.V. during the association's General Assembly on 23 September 2011.
[...]
ECTRIMS 2011 Amsterdam
Dr Wolf will attend the Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis from 19-22 October 2011 in Amsterdam.
[...]Workshop FIM and Phase II (Berlin)
Dr Christian Wolf will speak at the workshop "Pharmaentwicklung: Erstanwendung am Menschen und Phase II" on 28 October 2011 in Berlin-Buch.
[...]
Drug-Related PML: Transatlantic Workshop
Dr Wolf will attend the Transatlantic workshop: drug-related progressive multifocal leukoencephalopathy from 25-26 July 2011 in London.
[...]
CSF and Blood Biobanking
just published and co-authored by Dr Wolf:
Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.
[...]